We Compiled the Most Important Facts About Welltower

By Susan Ramirez • Wednesday, August 23 12:29 • Permanent Link

More and more people are talking about Welltower over the last few weeks. Is it worth buying the Specialty Real Estate Investment Trust stock at a price of $80.74? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Welltower has moved 6.0% over the last year, and the S&P 500 logged a change of 8.0%
WELL has an average analyst rating of buy and is -7.39% away from its mean target price of $87.18 per share
Its trailing earnings per share (EPS) is $0.26
Welltower has a trailing 12 month Price to Earnings (P/E) ratio of 310.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $1.08 and its forward P/E ratio is 74.8
The company has a Price to Book (P/B) ratio of 1.93 in contrast to the S&P 500's average ratio of 2.95
Welltower is part of the Real Estate sector, which has an average P/E ratio of 24.81 and an average P/B of 2.24
WELL has reported YOY quarterly earnings growth of 4.1% and gross profit margins of 0.4%
The company has a free cash flow of $1.49 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Welltower Inc. (NYSE:WELL), a real estate investment trust ("REIT") and S&P 500 company headquartered in Toledo, Ohio, is driving the transformation of health care infrastructure. Welltower invests with leading seniors housing operators, post-acute providers and health systems to fund the real estate infrastructure needed to scale innovative care delivery models and improve people's wellness and overall health care experience. Welltower, owns interests in properties concentrated in major, high-growth markets in the United States, Canada and the United Kingdom, consisting of seniors housing and post-acute communities and outpatient medical properties.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.